Shows & Panels
- Accelerate and Streamline for Better Customer Service
- Ask the CIO
- The Big Data Dilemma
- Carrying On with Continuity of Operations
- Client Virtualization Solutions
- Data Protection in a Virtual World
- Expert Voices
- Federal Executive Forum
- Federal IT Challenge
- Federal Tech Talk
- Feds in the Cloud
- Health IT: A Policy Change Agent
- IT Innovation in the New Era of Government
- Making Dollars And Sense Out of Data Center Consolidation
- Navigating the Private Cloud
- One Step to the Cloud, Two Steps Toward Innovation
- Path to FDCCI Compliance
- Take Command of Your Mobility Initiative
Shows & Panels
Barlow Herget Commentary
Barlow Herget is a commentator and host on State Government Radio at Curtis Media. He has been a commentator on UNC public radio and an instructor in continuing education at Duke University. Herget was a Nieman Fellow ('70) at Harvard University, has worked for the Daily Press of Paragould, Ark., the Detroit Free Press, and the News & Observer of Raleigh. His articles have appeared in The Atlantic, The New York Times and numerous other publications. Contact him by email.
Tuesday - 3/27/2012, 1:07pm EDT
This is a big company based in California. I didn't receive a return letter. Instead, I received a telephone call left on my answering machine. (As an old reporter, I've grown suspicious when someone prefers a call to a written document.) The caller said she would call back. She never did.
After another letter and a phone call, I talked to a registered nurse who sounded like she was reading from a script. Their drugs were FDA approved and of the highest quality, she assured me.
I finally got her to tell me where the manufacturers were located, both in the United States, but she admitted she didn't know where the manufacturers purchased their chemicals.
When I mentioned this to one of my doctors, he commiserated with me and handed me a 2009 New York Times article. My doctor told me that even if I contacted the manufacturer, the drug-maker would not have to tell me where it bought its chemical ingredients. Such information is considered a trade secret, according to the news article.
Now consider this. 43 percent of America's generic drugs are made in China and 39 percent in India. The record on chemicals from these two countries is written in blood, literally. Their drugs are often shipped in powder form to U.S. plants where they are pounded into pills and packaged with U.S. labels.
Yes, the FDA does inspect Chinese and Indian plants but not nearly as often as their counterparts in the United States.
The New York Times won a Pulitzer Prize for a series in 2007 and 2008 on counterfeit drugs from China. More recently, CBS' 60 Minutes showed its viewers a dirty laboratory in Lima, Peru, where more bad, counterfeit drugs were being manufactured and packaged for sale abroad.
American drug manufacturers are very worried about the flood of foreign, counterfeit drugs. So is the FDA. Margaret Hamburg, the FDA's commissioner, told CBS, "We don't really know the full dimensions of the problem. But, we do know that in certain countries somewhere between 30 and 50 percent of really important drugs for health are, in fact, counterfeit."
There are many anti-government Americans who argue against more regulation. Let the free market sort out the good from the bad.
I tried to sort out who makes my drugs and got nowhere. How about you? Do you think you and the free market can tell good from bad medicine?